{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:42Z","timestamp":1792039602083,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lungcan.2026.109637","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:26:31Z","timestamp":1790519191000},"page":"109637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world progression-free survival with erlotinib versus osimertinib in EGFR L858R\u00a0+\u00a0T790M compound mutation non-small cell lung Cancer: An exploratory analysis of the MSK-CHORD dataset"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3773-9151","authenticated-orcid":false,"given":"Zeinab","family":"Dalloul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5002-499X","authenticated-orcid":false,"given":"Ahmad","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0007","authenticated-orcid":false,"given":"Iman","family":"Dalloul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4971-5181","authenticated-orcid":false,"given":"Mahmoud","family":"Abdelsalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lungcan.2026.109637_b0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109637_b0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109637_b0015","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109637_b0020","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3(75):75ra26","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109637_b0025","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109637_b0030","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109637_b0035","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.lungcan.2026.109637_b0040","article-title":"Insensitivity to T790M mutation? a pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon EGFR mutations","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lungcan.2026.109637_b0045","doi-asserted-by":"crossref","first-page":"9621","DOI":"10.2147\/CMAR.S216721","article-title":"Poor prognosis with coexistence of EGFR T790M mutation and common EGFR-activating mutation in non-small cell lung cancer","volume":"11","author":"Gao","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109637_b0050","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4172\/1948-5956.1000569","article-title":"EGFR primary T790M and L858R double mutation confers clinical benefit to erlotinib and resistance to osimertinib in one lung adenocarcinoma patient","volume":"10","author":"Zhao","year":"2018","journal-title":"J Cancer Sci Ther."},{"key":"10.1016\/j.lungcan.2026.109637_b0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.lungcan.2018.08.014","article-title":"High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation","volume":"124","author":"Tian","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109637_b0060","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41586-024-08167-5","article-title":"Automated real-world data integration improves cancer outcome prediction","volume":"636","author":"Jee","year":"2024","journal-title":"Nature"},{"issue":"40","key":"10.1016\/j.lungcan.2026.109637_b0065","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21105\/joss.01317","article-title":"lifelines: survival analysis in Python","volume":"4","author":"Davidson-Pilon","year":"2019","journal-title":"J Open Source Softw."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109637_b0070","article-title":"Distinct progression and efficacy of first-line osimertinib treatment according to mutation subtypes in metastatic NSCLC harboring EGFR mutations","volume":"5","author":"Takeyasu","year":"2024","journal-title":"JTO Clin Res Rep."},{"key":"10.1016\/j.lungcan.2026.109637_b0075","first-page":"17","article-title":"Comparison of erlotinib vs. osimertinib for advanced or metastatic EGFR mutation-positive NSCLC without prior treatment: a network meta-analysis","author":"Runzer-Colmenares","year":"1895","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/j.lungcan.2026.109637_b0080","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The Allelic Context of the C797S Mutation acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to subsequent Treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109637_b0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2017.02.019","article-title":"Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer","volume":"108","author":"Hidaka","year":"2017","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109637_b0090","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/dnares\/dsx027","article-title":"Sequencing and phasing cancer mutations in lung cancers using a long-read portable sequencer","volume":"24","author":"Suzuki","year":"2017","journal-title":"DNA Res."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109637_b0095","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2011.38.3224","article-title":"Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer","volume":"30","author":"Su","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109637_b0100","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1158\/1078-0432.CCR-10-2158","article-title":"Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations","volume":"17","author":"Rosell","year":"2011","journal-title":"Clin. Cancer Res."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:09:41Z","timestamp":1792037381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":20,"alternative-id":["S0169500226006987"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109637","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world progression-free survival with erlotinib versus osimertinib in EGFR L858R\u00a0+\u00a0T790M compound mutation non-small cell lung Cancer: An exploratory analysis of the MSK-CHORD dataset","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109637"}}